Freeline Therapeutics Holdings plc Return on Equity

The latest ROE for FRLN is -166.22%. That is below the Healthcare sector average of 11.15%. Investors often review this figure alongside Freeline Therapeutics Holdings plc's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, FRLN currently prints -166.22% for ROE, while the sector average sits near 11.15%. That is roughly 1590.2% below the sector mean. Large gaps often invite a closer look at Freeline Therapeutics Holdings plc's growth, margins, and balance sheet.

Return on Equity shows how effectively Freeline Therapeutics Holdings plc converts resources into returns. At -166.22%, FRLN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FRLN's ROE (-166.22%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Freeline Therapeutics Holdings plc's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.